We did not find any evidence of an association between CYP17 genotype and stage of breast cancer, with 65.5% of those with local disease and 68.1% of those with the advanced disease, respectively, being carriers of the A2 allele. This evidence concerns the gene CYP17A1 and breast carcinoma.